Incyte reported at ESMO that a targeted treatment used in combination with chemotherapy produced lasting tumor responses in certain pancreatic cancer patients, supporting the company’s plan to advance the program into a late-stage trial. The update comes as next-generation approaches are increasingly benchmarked not only by response rates but also by durability. The ESMO presentation positions Incyte among a broader set of companies developing mutation-selective RAS-family therapies in pancreatic cancer, where early-line competition is accelerating following precedent RAS-targeted successes.